Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
about
The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implicationsNovel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.Targeted polymeric therapeutic nanoparticles: design, development and clinical translationEffective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cellsPresent trend in the primary treatment of aggressive malignant glioma: glioblastoma multiforme.The ability of hyaluronan fragments to reverse the resistance of C6 rat glioma cell line to temozolomide and carmustine.Tumor cohesion and glioblastoma cell dispersal.Nanotherapeutic systems for local treatment of brain tumors.Nanoengineered drug-releasing Ti wires as an alternative for local delivery of chemotherapeutics in the brainCarmustine-induced phosphatidylserine translocation in the erythrocyte membrane.A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells.Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.
P2860
Q26829663-23AA189E-5944-4186-9DCC-A25A71CE131EQ30474002-0CFB70B9-4E7A-472B-9B5E-0E38785ABFAAQ34048935-6A92CBD4-4CAB-4E17-948B-8E23168ADA24Q35845231-5D63858D-590A-4E5B-80D2-6E5D0AF9F0D4Q36312905-CA994EB3-4AF3-4686-BE2F-FDC35CA3888AQ36357995-EFA8BA5E-E997-4376-8C61-728D39AC4142Q36934007-C67F702F-768B-454B-A1F8-0D6ABC0EA52BQ37091154-49163765-60B7-4CB5-BCE6-9603AEAEF77FQ37160479-65642DEB-34F5-4F99-A810-BDC776769BA8Q38932015-5404631C-FF9B-447E-A671-774191B83D0BQ39117565-9FFEC1D0-7CD4-48F5-84D4-CB4D88DA7ABFQ39330269-D9D674F3-99D0-461E-B81E-12CB99A5939AQ42090018-6BE48F95-732A-49E5-8993-036405FDDF8AQ42181197-5490B550-4C80-42D1-8FE9-CBE75E7E4A2FQ55012542-D1B76F8A-1B31-475D-BC24-82655F41B3F7Q55461270-F61AC51D-8019-4B85-8AA8-F8A274C1FED0
P2860
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@en
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@nl
type
label
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@en
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@nl
prefLabel
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@en
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@nl
P2860
P356
P1476
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
@en
P2093
Lawrence R Kleinberg
Steven H Lin
P2860
P304
P356
10.1586/14737140.8.3.343
P577
2008-03-01T00:00:00Z